Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Inclusion Criteria: 1. Age of 18-75 years; 2. Cytological or histological diagnosis of recurrent or metastatic gastric adenocarcinoma; 3. At least one measurable lesion as defined by RECIST 1.1 criteria; 4. ECOG performance status of 0-1; 5. Estimated life expectancy of at least 3 months; 6. Left ventricular ejection fraction (LVEF) ≥ 50%; 7. Bone marrow function: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥90×109 /L, hemoglobin(HB) ≥90 g/L; 8. Liver and kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN), or ≤5 x upper limit of normal range (ULN)when with hepatic metastases，total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN), or≤2.5 x upper limit of normal range (ULN) when with Gilbert's syndrome; 9. Not be breast-feeding; men and women of reproductive age are willing to take reliable contraceptive measures during the study; 10. Able and willing to comply with the study plans in this protocol and sign the informed consent; Exclusion Criteria: 1. Have received chemotherapy before；patients that received neoadjuvant or adjuvant chemotherapy are eligible provided the treatment is completed\>6 months prior to first recurrence or metastasis; 2. HER-2 positive; 3. Patients with symptomatic brain metastases; 4. II-IV peripheral neuropathy \[NCI-CTCAE 4.03\]; 5. Anti-HCV antibody positive and HCV-RNA positive; anti-HBV antibody positive with active hepatitis ; anti-HIV antibody positive; 6. Patients with serious systemic infection or other diseases; 7. Allergic to the chemotherapy drugs or the materials in this study; 8. Patients with gastrointestinal bleeding that need clinical intervention; 9. Patients with digestive tract obstruction or oral nutrition difficulty; 10. Have a second malignancy within 5 years prior to registration except for cured carcinoma in situ of cervix uteri, non-melanoma skin cancer; 11. Have participated in other clinical trials within 28 days prior to the first dose of this study; 12. Contraindications to chemotherapy; 13. Patients that researcher consider cannot sign informed consent or complete the study plan due to medical science factor, social factor or psychological reasons.